Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.
Vavala T, Malapelle U, Veggiani C, Ludovini V, Papotti M, Leone A, Graziano P, Minari R, Bono F, Sapino A, Manotti L, Troncone G, Pisapia P, Girlando S, Buffoni L, Righi L, Colantonio I, Bertetto O, Novello S. Vavala T, et al. Among authors: ludovini v. J Clin Pathol. 2022 Apr;75(4):234-240. doi: 10.1136/jclinpath-2020-207339. Epub 2021 Jan 28. J Clin Pathol. 2022. PMID: 33509945
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinò L. Cappuzzo F, et al. Among authors: ludovini v. J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41. doi: 10.1093/jnci/djh217. J Natl Cancer Inst. 2004. PMID: 15292385 Clinical Trial.
Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, Semeraro A, Daddi G, Darwish S, Stocchi L, Tofanetti FR, Bellezza G, Sidoni A, Tognellini R, Crinò L, Tonato M. Ludovini V, et al. Tumori. 2008 May-Jun;94(3):398-405. doi: 10.1177/030089160809400317. Tumori. 2008. PMID: 18705409
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L. Ludovini V, et al. J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b. J Thorac Oncol. 2011. PMID: 21258250 Free article.
Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation.
Metro G, Chiari R, Mare M, Giannarelli D, Tofanetti FR, Minotti V, Ferraldeschi M, Giuffrida D, Marcomigni L, Bennati C, Fischer MJ, Meacci M, Bellavita R, Pistola L, Ludovini V, Crinò L. Metro G, et al. Among authors: ludovini v. Cancer Chemother Pharmacol. 2011 Dec;68(6):1405-12. doi: 10.1007/s00280-011-1632-x. Epub 2011 Apr 6. Cancer Chemother Pharmacol. 2011. PMID: 21468755
Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, Garavaglia D, Tofanetti FR, Flacco A, Siggillino A, Baldelli E, Tonato M, Crinò L. Ludovini V, et al. J Thorac Oncol. 2011 Dec;6(12):2018-26. doi: 10.1097/JTO.0b013e3182307e1f. J Thorac Oncol. 2011. PMID: 22052224 Free article.
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
Ludovini V, Bianconi F, Pistola L, Pistola V, Chiari R, Colella R, Bellezza G, Tofanetti FR, Siggillino A, Baldelli E, Flacco A, Giuffrida D, Sidoni A, Crinò L. Ludovini V, et al. Cancer Chemother Pharmacol. 2012 May;69(5):1289-99. doi: 10.1007/s00280-012-1829-7. Cancer Chemother Pharmacol. 2012. PMID: 22302407
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
Metro G, Chiari R, Duranti S, Siggillino A, Fischer MJ, Giannarelli D, Ludovini V, Bennati C, Marcomigni L, Baldi A, Giansanti M, Minotti V, Crinò L. Metro G, et al. Among authors: ludovini v. Lung Cancer. 2012 Oct;78(1):81-6. doi: 10.1016/j.lungcan.2012.06.005. Epub 2012 Jul 4. Lung Cancer. 2012. PMID: 22770374
93 results